Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetically proxied IL-6 signaling inhibition, lipoprotein(a) levels, and atherosclerotic disease risk.

Atherosclerosis - 1 Apr 2026

Daghlas Iyas, Georgakis Marios K, Brennan Stephen O, Arsenault Benoit J, Burgess Stephen, Gill Dipender

Abstract excerpt

BACKGROUND: Clinical trials have shown that interleukin-6 (IL-6) signaling inhibitors reduce lipoprotein(a) [Lp(a)] levels, though the relevance of this reduction to atherosclerotic cardiovascular disease (ASCVD) risk is uncertain. We leveraged Mendelian randomization (MR) to investigate the extent to which Lp(a) reduction mediates the effects of IL-6 signaling inhibition on ASCVD. METHODS: IL-6 signaling...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atherosclerosis
Share to C-Reactive Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carotid Artery Diseases

Share to Interleukin-6

Share to Lipoprotein(a)

Share to Plaque, Atherosclerotic

Share to Receptors, Interleukin-6

Share to Stroke

Source

Identifiers

PMID: 41932221
DOI: 10.1016/j.atherosclerosis.2026.120723

Genes

CAD
CRP
IL6R

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetically proxied IL-6 signaling inhibition, lipoprotein(a) levels, and atherosclerotic disease risk.PMID 41932221Read ↗

Additive Effects of Genetic Interleukin‐6 Signaling Downregulation and Low‐Density Lipoprotein Cholesterol Lowering on Cardiovascular Disease: A 2×2 Factorial Mendelian Randomization AnalysisSemantic proximity Read ↗

Proteogenomic integration reveals CXCL10 as a potentially downstream causal mediator for IL-6 signaling on atherosclerosisSemantic proximity Read ↗

Interleukin-6 signaling effects on ischemic stroke and other cardiovascular outcomes: a Mendelian Randomization studySemantic proximity Read ↗

Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on AtherosclerosisSemantic proximity Read ↗

Dissecting the IL-6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R.Semantic proximity Read ↗

Genetically downregulated interleukin-6 signaling is associated with a favorable cardiometabolic profile: a phenome-wide association studySemantic proximity Read ↗

Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.Semantic proximity Read ↗

Proteomic Insights into Lp(a) Cardiovascular Mechanisms: A Mendelian Randomization StudySemantic proximity Read ↗

Evaluating genetically-predicted causal effects of lipoprotein(a) in human diseases: a phenome-wide Mendelian randomization studySemantic proximity Read ↗

Genetic downregulation of interleukin-6 signaling and arteriolosclerotic cerebral small vessel disease: a drug target Mendelian randomization analysisSemantic proximity Read ↗

Genetically Predicted IL-18 Inhibition and Risk of Cardiovascular Events: A Mendelian Randomization StudySemantic proximity Read ↗

Role of interleukin 6 signaling pathway in the anti-inflammatory effects of statins on coronary artery disease: Evidence from Mendelian randomization analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.